V. Gross

发表

Regulation of interleukin-8 production in a human colon epithelial cell line (HT-29).

J. Schölmerich, W. Falk, V. Gross, 1995, Gastroenterology.

Etiology and pathophysiology of inflammatory bowel disease--environmental factors.

V. Gross, T. Andus, 2000, Hepato-gastroenterology.

Activation of monocytes during inflammatory bowel disease.

J. Schölmerich, V. Gross, T. Andus, 1991, Pathobiology : journal of immunopathology, molecular and cellular biology.

High concentrations of soluble tumor necrosis factor receptors in ascites

J. Schölmerich, W. Gerok, V. Gross, 1992, Hepatology.

Patient education in inflammatory bowel disease does not influence patients knowledge and long-term psychosocial well-being.

V. Gross, T. Andus, J. Schölmerich, 2005, Zeitschrift fur Gastroenterologie.

Evidence for continuous stimulation of interleukin-6 production in Crohn's disease.

J. Schölmerich, V. Gross, T. Andus, 1992, Gastroenterology.

Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease.

W. Falk, V. Gross, T. Andus, 1996, Gut.

Effect of programmed endoscopic follow-up examinations on the rebleeding rate of gastric or duodenal peptic ulcers treated by injection therapy: a prospective, randomized controlled trial.

J. Schölmerich, H. Messmann, T. Lingenfelser, 1998, Endoscopy.

Detection of dysplastic lesions by fluorescence in a model of colitis in rats after previous photosensitization with 5-aminolaevulinic acid.

J. Schölmerich, J. Rüschoff, H. Messmann, 1998, Endoscopy.

Imbalance of the interleukin 1 system in colonic mucosa—association with intestinal inflammation and interleukin 1 receptor agonist genotype 2

S. Hollerbach, D. Vogl, V. Gross, 1997 .

Inflammatory mediators in chronic inflammatory bowel diseases

V. Gross, T. Andus, J. Schölmerich, 1991, Klinische Wochenschrift.

Update gastroenterologie 1997 — Teil I

C. Ell, J. Schölmerich, P. Layer, 1998, Medizinische Klinik.

Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease

J. Schölmerich, R. Straub, D. Vogl, 1998, American Journal of Gastroenterology.

Evidence for the production of high amounts of interleukin-6 in the peritoneal cavity of patients with ascites.

J. Schölmerich, W. Gerok, V. Gross, 1992, Journal of hepatology.

Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis

V. Gross, 2008, Expert opinion on pharmacotherapy.

Free radicals in inflammatory bowel diseases pathophysiology and therapeutic implications.

V. Gross, T. Andus, J. Schölmerich, 1994, Hepato-gastroenterology.

Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn's ileocolitis depending on disease activity and localization

H. Herfarth, G. Adler, V. Gross, 2004, International Journal of Colorectal Disease.

Strictures in Crohn’s disease are characterised by an accumulation of mast cells colocalised with laminin but not with fibronectin or vitronectin

W. Falk, V. Gross, J. Schölmerich, 1999, Gut.

Imbalance of the interleukin 1 system in colonic mucosa--association with intestinal inflammation and interleukin 1 receptor antagonist [corrected] genotype 2.

S. Hollerbach, D. Vogl, V. Gross, 1997, Gut.

Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group.

W. Fischbach, F. Hartmann, V. Gross, 1995, Zeitschrift fur Gastroenterologie.

Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group.

J. Schölmerich, K. Ewe, S. Bischoff, 1996, European journal of gastroenterology & hepatology.

Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI.

W. Petritsch, D. Genser, P. Mortensen, 2000, Gastroenterology.

Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn’s disease

K. Ewe, V. Gross, T. Andus, 1998 .

Prior bowel resections, perianal disease, and a high initial Crohn's disease activity index are associated with corticosteroid resistance in active Crohn's disease

G. Rogler, J. Schölmerich, V. Gross, 2002, American Journal of Gastroenterology.

A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease.

J. Schölmerich, H. Peter, V. Gross, 1990, Immunobiology.

PMN-elastase in assessment of patients with inflammatory bowel disease

J. Schölmerich, W. Gerok, V. Gross, 1993, Digestive Diseases and Sciences.

Efficacy of different mesalamine-releasing drugs.

V. Gross, 1998, Gastroenterology.

Association of autonomic nervous hyperreflexia and systemic inflammation in patients with Crohn's disease and ulcerative colitis

J. Schölmerich, R. Straub, V. Gross, 1997, Journal of Neuroimmunology.

Angiotensin-converting enzyme (ACE)-inhibition in cirrhosis. Pharmacokinetics and dynamics of the ACE-inhibitor cilazapril (Ro 31-2848).

J. Schölmerich, V. Gross, K. Haag, 1993, Journal of hepatology.

Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or interleukin-6

G. Rogler, W. Falk, D. Vogl, 2000, Gut.

Can an early second-look endoscopy reduce recurrent bleeding of gastric of duodenal ulcers?

J. Schölmerich, H. Messmann, V. Gross, 1996 .

Establishment of long-term primary cultures of human small and large intestinal epithelial cells.

G. Rogler, W. Falk, D. Vogl, 1998, Laboratory investigation; a journal of technical methods and pathology.

Inflammatory mediators and cytokines--new aspects of the pathophysiology and assessment of severity of acute pancreatitis?

J. Schölmerich, V. Gross, H. Leser, 1993, Hepato-gastroenterology.

Elevation of serum interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis.

C. Scheibenbogen, J. Schölmerich, R. Andreesen, 1991, Gastroenterology.

Granulocyte elastase in assessment of severity of acute pancreatitis

J. Schölmerich, R. Salm, W. Gerok, 2005, Digestive Diseases and Sciences.

Neutralization of tumour necrosis factor (TNF) but not of IL‐1 reduces inflammation in chronic dextran sulphate sodium‐induced colitis in mice

W. Falk, D. Männel, F. Obermeier, 1997, Clinical and Experimental Immunology.

3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.

L. Kupčinskas, Z. Tulassay, G. Kiudelis, 2011, Journal of Crohn's & colitis.

Update Gastroenterologie 1997—Teil II

C. Ell, J. Schölmerich, P. Layer, 1998, Medizinische Klinik.

[1997 gastroenterology update--II].

C. Ell, J. Schölmerich, P. Layer, 1998, Medizinische Klinik.

Scintigraphic assessment of leukocyte infiltration in acute pancreatitis using technetium-99m-hexamethyl propylene amine oxine as leukocyte label

C. Schümichen, M. Lausen, E. Farthmann, 2005, Digestive Diseases and Sciences.

Value of endoscopic retrograde cholangiopancreatography in determining the cause but not course of acute pancreatitis.

J. Schölmerich, R. Salm, M. Lausen, 1992, Endoscopy.

[Sonography in acute pancreatitis--diagnosis, assessment of etiology and evaluating prognosis].

J. Schölmerich, W. Gerok, E. Farthmann, 2008, Ultraschall in der Medizin.

Endoscopic retrograde cholangiopancreatography in acute pancreatitis

H. Brambs, J. Schölmerich, V. Gross, 1988 .

T-cell co-stimulatory molecules are upregulated on intestinal macrophages from inflammatory bowel disease mucosa.

G. Rogler, W. Falk, M. Hausmann, 1999, European journal of gastroenterology & hepatology.

Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa.

R. Knuechel, G. Rogler, J. Schölmerich, 1998, Gastroenterology.

Alterations of the phenotype of colonic macrophages in inflammatory bowel disease

G. Rogler, J. Schölmerich, W. Falk, 1997, European journal of gastroenterology & hepatology.

Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis

A. Lavy, L. Kupčinskas, Z. Tulassay, 2006, Alimentary pharmacology & therapeutics.

Prior bowel resections, perianal disease, and a high initial Crohn's disease activity index are associated with corticosteroid resistance in active Crohn's disease.

G. Rogler, J. Schölmerich, V. Gross, 2002 .

Expression of proliferating cell nuclear antigen (PCNA) and Ki‐67 in dysplasia in inflammatory bowel disease

J. Schölmerich, J. Rüschoff, R. Knüchel, 1996, European journal of gastroenterology & hepatology.

lnterleukin‐8 and neutrophil activation in acute pancreatitis

J. Schölmerich, R. Andreesen, M. Ceska, 1992, European journal of clinical investigation.

Treatment of active Crohn's disease with an oral slow-release budesonide formulation.

K. Ewe, V. Gross, J. Schölmerich, 1993, The American journal of gastroenterology.

Focal white-matter lesions in brain of patients with inflammatory bowel disease

S. Feuerbach, S. Feuerbach, P. Held, 1995, The Lancet.

Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group.

K. Ewe, V. Gross, T. Andus, 1998, Gut.

Clinical trial: randomized‐controlled clinical study comparing the efficacy and safety of a low‐volume vs. a high‐volume mesalazine foam in active distal ulcerative colitis

A. Lavy, L. Kupčinskas, R. Eliakim, 2007, Alimentary pharmacology & therapeutics.

Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.

K. Ewe, V. Gross, T. Andus, 1997, Hepato-gastroenterology.

Topical Therapy

V. Gross, 2013, Digestive Diseases.

[Topical therapy of ulcerative colitis].

G. Rogler, C. Beglinger, F. Seibold, 2011, Praxis.

Aminosalicylates

V. Gross, 2012, Digestive Diseases.

Crohn's disease of the esophagus: treatment of an esophagobronchial fistula with the novel liquid embolic polymer "onyx".

G. Rogler, J. Schölmerich, H. Herfarth, 2006, Zeitschrift fur Gastroenterologie.

The role of the resident intestinal flora in acute and chronic dextran sulfate sodium‐induced colitis in mice

J. Schölmerich, W. Falk, V. Gross, 2000, European journal of gastroenterology & hepatology.

Clinical and histopathological features of dextran sulfate sodium induced acute and chronic colitis associated with dysplasia in rats

J. Schölmerich, J. Rüschoff, H. Messmann, 2001, International Journal of Colorectal Disease.

Beneficial effect of ursodeoxycholic acid on mucosal damage in trinitrobenzene sulphonic acid-induced colitis.

J. Schölmerich, J. Rüschoff, V. Gross, 1997, European journal of gastroenterology & hepatology.

Interleukin-12 induced interferon-gamma increases inflammation in acute dextran sulfate sodium induced colitis in mice.

W. Falk, V. Gross, J. Schölmerich, 2000, European cytokine network.

[Immunosuppression in inflammatory bowel disease: When, how and how long?].

V. Gross, 2012, Deutsche medizinische Wochenschrift.

Replacement of Conventional Glucocorticoids by Oral pH-Modified Release Budesonide in Active and Inactive Crohn's Disease: Results of an Open, Prospective, Multicenter Trial

K. Ewe, H. Lochs, V. Gross, 2003, Digestive Diseases and Sciences.

Effect of ursodeoxycholic acid on the inflammatory activity of indomethacin-induced intestinal inflammation in rats.

J. Schölmerich, J. Rüschoff, V. Gross, 1997, Zeitschrift fur Gastroenterologie.

Acute phase protein synthesis: Regulation by the action of the cytokines interleukin-6, interleukin-1 and tumor necrosis factor α

P. Heinrich, T. Geiger, J. Castell, 1989 .

[Crohn disease: prevention and drug therapy].

V. Gross, T. Andus, J. Schölmerich, 1995, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

Treatment of active Crohn's ileocolitis with oral pH-modified budesonide. Germany Budesonide Study Group.

K. Ewe, V. Gross, T. Andus, 1995, Zeitschrift für Gastroenterologie - German Journal of Gastroenterology.

High interleukin-6 concentrations in hepatic ascites

J. Schölmerich, V. Gross, T. Andus, 2005, Digestive Diseases and Sciences.

Efficacy, safety and biological profile of a new 2-litre gut cleansing solution with PEG3350 plus electrolytes in risk groups undergoing colonoscopy

C. Ell, P. Layer, W. Fischbach, 2005 .

Interferon‐gamma (IFN‐γ)‐ and tumour necrosis factor (TNF)‐induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)‐induced colitis in mice

W. Falk, F. Obermeier, V. Gross, 1999, Clinical and experimental immunology.

83 Efficacy and Tolerability of a Once Daily Treatment with Budesonide Capsules Versus Mesalamine Granules for the Treatment of Active Ulcerative Colitis: A Randomized, Double-Blind, Double-Dummy, Multicenter Study

L. Kupčinskas, Z. Tulassay, G. Kiudelis, 2009 .

Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease.

W. Falk, V. Gross, T. Andus, 1996, Gut.